Latest News

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

25 August 2022

New York, August 25, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

17 August 2022

New York, August 17, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity...

Read more

Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease

01 August 2022

  • - Study conducted in animal models of Alzheimer’s disease finds restored microglia homeostasis and improvement in cognition -

New York, August 1, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”),...

Read more

Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer

18 July 2022

New York, July 18, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has appointed Matthew Davis, MD, RPh as its...

Read more

Tiziana Life Sciences Announces Resignation of CEO

15 July 2022

New York, July 15, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that the Board of Directors has accepted the voluntary resignation...

Read more

Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

17 June 2022

Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

New York, June 17, 2022 – Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today disclosed...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

10 June 2022

New York, June 10, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity...

Read more

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

09 June 2022

New York, June 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity...

Read more

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

08 June 2022

  • A second patient also showed clinical improvements in the Positron Emission Tomography (PET) imaging analysis, neurologic exam, and in the Timed 25-Foot Walk test, following...

Read more

Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs

06 June 2022

NEW YORK – June 6, 2022 – Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration today announced that its Chief Executive Officer and Chief Scientific Officer,...

Read more

Page 2 of 23 Previous Next